10.10.25 -- Advancing Fill/Finish Excellence: Capabilities, Capacity, And Quality Updates

Join 1,000+ pharma, biotech, and drug delivery professionals at the PODD: Partnership Opportunities in Drug Delivery Conference conference, October 27–28 in Boston. Featuring 10 technology tracks, pharma company spotlights, 1:1 partnering, and more. Attendees will also hear from leaders at companies including AbbVie, Amgen, AstraZeneca, Biogen, Eli Lilly, GSK, Moderna, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and others. Register at PODDConference.com with code LSL20 for 20% off.

Uncover how comprehensive drug product fill and finish services streamline the journey from formulation development to commercialization, ensuring quality, efficiency, and compliance.

This presentation highlights how simplified execution with development, filling, and analytics under one roof ensures safe, efficacious products reach patients in need.

Ken Bonnell, Senior Vice President of Quality and Regulatory Affairs, shares insight on what to look for and what is important when evaluating quality systems with manufacturing partners.

This highly efficient process ensures that no microbial contaminants like fungi or bacteria are present when the product is used. If you have a product that needs to be terminally sterilized, we can help.

Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth.

Equipped with advanced isolators and RAB technologies, our aseptic filling facilities feature multiple filling lines capable of producing liquid and lyophilized vials as well as prefilled syringes.

Tara Lorenz, Sr. Director of Commercial Operations, speaks on our latest investments and expanded fill/finish capabilities and capacity for small molecules, biologics, and other sterile injectable products.

Showcasing advanced robotics, our automated fill line is specially designed to maximize product yield while minimizing the risks associated with operator intervention.